budgetmantra.in

Author: paisamatters44@gmail.com

  • ICAI CA September 2025 Date Sheet Out: Foundation, Inter & Final Exam

    The Institute of Chartered Accountants of India (ICAI) has released the official timetable for the CA September 2025 examinations, covering all three levels: Foundation, Intermediate, and Final. The exams are scheduled between September 3 and September 22, 2025.

    CA September 2025 Exam Schedule

    🔹 Final Course

    • Group I: September 3 (Wednesday), 6 (Saturday), and 8 (Monday)
    • Group II: September 10 (Wednesday), 12 (Friday), and 14 (Sunday)
    • Paper 6: September 14 (Sunday)

    🔹 Intermediate Course

    • Group I: September 4 (Thursday), 7 (Sunday), and 9 (Tuesday)
    • Group II: September 11 (Thursday), 13 (Saturday), and 15 (Monday)

    🔹 Foundation Course

    • Paper 1: September 16 (Tuesday)
    • Paper 2: September 18 (Thursday)
    • Paper 3: September 20 (Saturday)
    • Paper 4: September 22 (Monday)

    Exam Timings

    • Foundation:
      • Papers 1 & 2: 2:00 PM – 5:00 PM
      • Papers 3 & 4: 2:00 PM – 4:00 PM
    • Intermediate: All papers from 2:00 PM – 5:00 PM
    • Final:
      • Papers 1 to 5: 2:00 PM – 5:00 PM
      • Paper 6: 2:00 PM – 6:00 PM

    Important Notes

    • No examinations will be held on September 5, 2025, due to the Milad-un-Nabi holiday.
    • If any other exam date coincides with a public holiday declared by the Central or State Government, the exam schedule will remain unchanged.

    Application Process

    • Application Window: July 5 to July 18, 2025
    • How to Apply:
      • Visit the official ICAI website: icai.org
      • Navigate to the “Examinations” section.
      • Fill out the online application form.
      • Upload required documents and pay the examination fee

    Preparation Tips

    • Start early and create a realistic study schedule.
    • Focus on understanding concepts rather than rote learning.
    • Regularly revise and practice past examination papers.
    • Join study groups or coaching classes if needed.
    • Ensure adequate rest and maintain a healthy routine.

    For detailed information and updates, regularly check the official ICAI website: icai.org

  • SBI Q4 : ₹16,000+ करोड़ के Loan माफ किए गए – निवेशकों के लिए इसका क्या मतलब है

    India’s largest public sector lender, State Bank of India (SBI), announced its Q4 results for FY25 with some mixed signals — a dip in profit, aggressive write-offs, and improving asset quality. Let’s break down the key highlights and what it means for you as an investor or market watcher.

    Net Profit Drops Despite Healthy Growth

    SBI reported a net profit of ₹18,643 crore in the January–March 2025 quarter (Q4FY25), which is down 9.9% year-on-year compared to ₹20,698 crore in Q4FY24. This decline was mainly due to:

    • Higher provisions
    • One-time adjustments
    • Increased loan write-offs

    ₹16,076 करोड़ के लोन किए गए राइट-ऑफ

    Q4 में SBI ने ₹16,076 करोड़ के खराब कर्ज (Bad Loans) को राइट-ऑफ (Write-Off) किया, जो पिछले साल के ₹8,595 करोड़ से लगभग दोगुना है।

    लोन राइट-ऑफ का मतलब क्या है?
    इसका अर्थ यह नहीं कि बैंक ने लोन माफ कर दिया — यह एक लेखा प्रक्रिया (accounting process) है जिससे बैलेंस शीट साफ होती है। वसूली की प्रक्रिया फिर भी जारी रहती है।

    SBI का उद्देश्य: पुरानी खराब संपत्तियों को हटाकर बैलेंस शीट को साफ करना और भविष्य के लिए मजबूत बनाना।

    Asset Quality Improves

    Despite the high write-offs, SBI’s asset quality improved significantly:

    • Gross NPA ratio: Improved to 1.82% from 2.24% (Q4FY24)
    • Net NPA ratio: Down to 0.47% from 0.57%
    • Provision Coverage Ratio (PCR): A strong 92.08%

    This shows SBI is in a much better position to absorb shocks and maintain financial stability.

    Financial Highlights

    MetricQ4FY25
    Net Profit₹18,643 Cr
    Loan Write-offs₹16,076 Cr
    Gross NPA1.82%
    Net NPA0.47%
    Deposits₹53.8 Lakh Cr (9.48% YoY growth)
    Home Loan Growth14.46% YoY
    Advances Growth~12-13% YoY

    Capital Raising Plans Ahead

    SBI plans to raise ₹25,000 crore in FY26 through various modes:

    • Follow-on Public Offer (FPO)
    • Rights Issue
    • Qualified Institutional Placement (QIP)

    This will help strengthen its capital base, expand lending, and fuel future growth.

    निष्कर्ष

    हालांकि मुनाफे में गिरावट और राइट-ऑफ की संख्या बड़ी है, SBI की बैलेंस शीट अब पहले से ज़्यादा साफ और मजबूत हो चुकी है।
    प्रोविजनिंग हाई है, NPA कम हुआ है, और बैंक भविष्य की ग्रोथ के लिए तैयार दिख रहा है।

    निवेशकों के लिए संकेत: SBI अपने खराब कर्जों को सुलझाकर लंबी अवधि की स्थिरता की ओर बढ़ रहा है।

  • Top 5 Mutual Funds for Lumpsum Investment with a 5-Year Horizon 2025

    Planning to invest a lumpsum amount for 5 years? That’s a smart move — long enough to ride out short-term volatility and potentially build strong returns. But picking the right mutual fund matters more than just parking money randomly.

    Here are the top 5 mutual funds in India for a 5-year lumpsum investment goal:

    1. Parag Parikh Flexi Cap Fund

    Category: Flexi Cap Fund
    Why Choose It:

    • Diversified across large caps, mid caps, and international equities
    • Focuses on value investing and long-term wealth building
    • Managed by a respected team with a conservative approach

    5-Year CAGR (Approx.): 17–18%
    Risk Level: Moderately High
    Best For: Investors wanting steady returns with some global exposure

    2. Motilal Oswal Flexi Cap Fund

    Category: Flexi Cap Fund
    Why Choose It:

    • Focused portfolio of high-conviction stocks (Buy Right, Sit Tight strategy)
    • Concentrated bets in quality businesses
    • Strong long-term performance with occasional short-term volatility

    5-Year CAGR (Approx.): 16–18%
    Risk Level: High
    Best For: Aggressive investors who trust in focused, long-term strategies

    3. Nippon India Large Cap Fund

    Category: Large Cap Fund
    Why Choose It:

    • Invests in top 100 Indian companies
    • Aggressive management with strong track record
    • Great potential for upside in a bullish market

    5-Year CAGR (Approx.): 15–17%
    Risk Level: Moderately High
    Best For: Investors looking for large-cap growth with active management

    4. Canara Robeco Emerging Equities Fund

    Category: Large & Mid Cap Fund
    Why Choose It:

    • Balanced mix of stability (large caps) and high-growth (mid caps)
    • Lower volatility than pure mid-cap funds
    • One of the most consistent performers in its category

    5-Year CAGR (Approx.): 16–18%
    Risk Level: Moderately High
    Best For: Balanced investors aiming for strong 5-year returns

    5. Quant Active Fund

    Category: Multi Cap Fund
    Why Choose It:

    • Tactical, fast-moving fund with unique sector calls
    • High alpha potential, suitable for risk-tolerant investors
    • Strong recent track record across time frames

    5-Year CAGR (Approx.): 18–20%
    Risk Level: High
    Best For: Bold investors willing to handle short-term swings for high returns

    Tips for Lumpsum Investing

    • STP Strategy: If you’re nervous about market timing, invest in a liquid fund and use an STP (Systematic Transfer Plan) to enter gradually.
    • Know Your Risk Profile: Choose funds that match your risk comfort — not just based on past returns.
    • Track Performance: Reassess every 6–12 months. Look for consistent performers, not one-time stars.
    • Tax Alert: Equity mutual fund gains beyond ₹1 lakh/year (after 1 year) attract 10% LTCG tax.

    Conclusion

    5-year investment horizon is ideal for building real wealth with equity mutual funds. The five funds listed above cover a mix of flexi-cap, large-cap, and multi-cap strategies — giving you a balanced portfolio tailored for growth, safety, or high risk-high return.

    DISCLAIMER: This Blog is for informational purposes only and should not be construed as investment advice. Stock markets are subject to risks; please invest based on your risk profile

  • Suzlon Energy Q4 FY25 Results: A Landmark Quarter for India’s Wind Energy Pioneer

    Suzlon Energy has delivered a standout performance in the fourth quarter of FY25, marking a significant turnaround and reaffirming its leadership in India’s renewable energy sector.

    Financial Highlights

    • Net Profit: Surged by 365% year-on-year (YoY) to ₹1,182 crore, up from ₹254 crore in Q4 FY24. This remarkable increase was bolstered by a deferred tax gain of ₹600 crore.
    • Revenue: Grew by 73% YoY to ₹3,773 crore, compared to ₹2,179 crore in the same quarter last year.
    • EBITDA: Increased by 94% YoY to ₹693 crore, with margins expanding by 200 basis points.
    • Full-Year Performance: For FY25, net profit rose to ₹2,072 crore from ₹660 crore in FY24, while revenue increased by 67% to ₹10,851 crore.

    Operational Milestones

    • Deliveries: Achieved a record 1,550 MW in FY25, a 118% increase from 710 MW in FY24.
    • Order Book: The S144 platform’s order book surpassed 5 GW, establishing it as a dominant product in the Indian market.
    • Net Cash Position: Improved to ₹1,943 crore as of March 2025, up ₹836 crore from December 2024.

    Market Reaction

    Following the announcement, Suzlon Energy’s shares surged by 13% in early trading on May 30, 2025, reaching a high of ₹73.81 on the BSE.

    Analyst Insights

    Analysts attribute Suzlon’s robust performance to strong project execution, improved operational efficiency, and a favorable policy environment for renewable energy in India. The company’s strategic focus on its S144 platform and expansion of its manufacturing capacity have positioned it well to capitalize on the growing demand for clean energy solutions.

    Conclusion

    Suzlon Energy’s Q4 FY25 results underscore its successful turnaround and resilience in the renewable energy sector. With a strong order book, improved financials, and a clear strategic direction, Suzlon is well-positioned to sustain its growth trajectory and contribute significantly to India’s clean energy goals.

  • Jio-BlackRock Receives SEBI Approval to Launch Mutual Fund Business in India

    In a significant development for India’s financial sector, Jio BlackRock Asset Management, a joint venture between Jio Financial Services Limited (JFSL) and global investment firm BlackRock, has secured approval from the Securities and Exchange Board of India (SEBI) to commence mutual fund operations.

    Technological Edge: The Aladdin Advantage

    A major talking point of this JV is Aladdin — BlackRock’s proprietary platform used by the biggest institutional investors globally for:

    • Risk analysis
    • Portfolio optimization
    • Predictive analytics

    Bringing this to Indian retail investors means better research, more transparency, and potentially smarter fund performance.

    Leadership and Vision :

    Sid Swaminathan, formerly the head of International Index Equity at BlackRock, has been appointed as the Managing Director and CEO of Jio BlackRock Asset Management. Under his leadership, the venture plans to leverage BlackRock’s renowned Aladdin platform—a comprehensive investment and risk management system—to deliver data-driven investment solutions.

    Market Implications :

    The entry of Jio BlackRock into the mutual fund space is expected to intensify competition among the existing 44 asset management companies in India, which collectively manage assets worth approximately ₹69.5 trillion (around $813.8 billion).

    What’s Next? Key Expectations from Jio-BlackRock in 2025 :

    Here are five things investors and competitors should look out for:

    1. Fund Launch Timeline: First products expected in Q3–Q4 of 2025
    2. Likely Fund Types:
      • Liquid funds for conservative investors
      • Index and ETF products for cost-conscious users
      • SIP-based retirement and tax-saving funds (ELSS)
    3. Exclusive Offers: Jio may offer zero-commission investments to onboard users quickly.
    4. Integrated App Launch: Likely integration within MyJio app, with standalone mutual fund features.
    5. Cross-Selling: Jio could cross-sell mutual funds alongside telecom, Jio Mart, and even insurance services.

    What Can Investors Expect Next?

    Likely Product Launches in H2 2025:

    • Liquid funds and ultra-short-term funds
    • Index-based and ETF products for low-cost investing
    • Retirement-oriented funds and SIP-focused tools

    Who Should Watch Out:

    • First-time investors
    • Tier-2 and Tier-3 city investors with Jio access
    • Young investors looking for transparent and tech-enabled options

    What Jio-BlackRock can change:

    ParameterStatus QuoPost Jio-BlackRock Entry
    DistributionAgents & apps like Zerodha, PaytmJio’s telecom and digital stack
    Investor OnboardingKYC bottlenecksInstant eKYC via Aadhaar/Jio
    Fund Pricing1-1.5% average expense ratioPossibly under 0.5% (if ETF/index)
    Investor DemographicsTier 1 & 2 focusTier 3 & rural expansion

    The Road Ahead: What to Expect Over 12–18 Months

    PhaseExpected Milestones
    📅 Q3 2025First set of fund launches (likely passive/index funds)
    📅 Q4 2025MyJio app integration and SIP rewards rollouts
    📅 Q1 2026Launch of thematic, hybrid, and retirement funds
    📅 H2 2026Possible international ETFs, tax-saving ELSS funds

    Conclusion: Should You Watch Out for Jio-BlackRock?

    Jio-BlackRock’s arrival is not just news — it’s a signal that India’s mutual fund industry is evolving fast. With its digital strength, capital backing, and global investment tools, this JV could democratize investing like never before.

    For investors, this means:

    • More choice
    • Lower costs
    • Easier access
    • Smarter tools

    If you’re looking to start your SIP journey or diversify your portfolio, keeping an eye on their upcoming NFOs (New Fund Offers) is a smart move.

  • Groww to Increase Brokerage Fees: Changes Effective June 21, 2025

    India’s leading discount brokerage platform, Groww, has announced a revision in its fee structure, set to take effect from June 21, 2025. This move comes amid rising operational costs and regulatory changes impacting the brokerage industry.

    Revised Fee Structure :

    1. Minimum Brokerage Fee:

    • Current: ₹2 per equity order
    • Revised: ₹5 per equity order

    This adjustment represents a 150% increase in the minimum brokerage fee, primarily affecting small-value equity trades.

    2. Depository Participant (DP) Charges:

    • Current: ₹18.5 per day per stock, regardless of the number of sale transactions
    • Revised: ₹20 per sale transaction

    Previously, Groww absorbed certain DP charges on behalf of clients. With the revised pricing, these charges will now be directly applicable to clients for each sell transaction.

    3. Margin Trading Facility (MTF) Interest Rate:

    • Current: 15.75% per annum for amounts below ₹25 lakh; 9.75% for ₹25 lakh and above
    • Revised: 14.95% per annum flat rate

    The MTF interest rate has been standardized to a flat rate, impacting clients utilizing margin trading services.

    Reasons Behind the Fee Hike :

    The decision to revise the fee structure is influenced by several factors:

    • Regulatory Changes: The Securities and Exchange Board of India’s (SEBI) ‘true-to-label’ norms have eliminated certain revenue streams for brokers, such as hidden markups and rebates, which previously contributed significantly to their income.
    • Operational Costs: Increasing expenses related to technology infrastructure and compliance have put pressure on brokerage firms to adjust their pricing models.

    Prakarsh Gagdani, CEO of Torus Financial Market, noted that the cost of doing broking business is compelling brokerages to hike rates.

    Client Communication and Industry Response :

    Groww communicated these changes to its clients via email, detailing the revised charges and their effective date. The brokerage emphasized that the adjustments are necessary to maintain service quality amid changing market dynamics.

    The fee revision has sparked discussions among investors and industry observers. Some clients have expressed concerns over the increased costs, especially for small-ticket trades. However, such adjustments are becoming common across the brokerage industry as firms adapt to evolving regulatory and economic landscapes.

    Conclusion :

    Groww’s upcoming fee revisions reflect broader trends in the brokerage industry, where firms are recalibrating their pricing structures in response to regulatory changes and operational challenges. Clients are advised to review the new fee schedule and assess its impact on their trading activities.

  • Zen Technologies Remarkable Rally: From ₹1,200 to ₹2,100 in May 2025

    In an extraordinary display of resilience and growth, Zen Technologies’ stock has surged from approximately ₹1,200 in early May to over ₹2,100 by the end of the month, marking a remarkable 75% increase within a single month.

    Stock Performance Overview

    Zen Technologies’ share price trajectory in May 2025 is as follows:

    • May 2, 2025: ₹1,389.50
    • May 9, 2025: ₹1,406.40
    • May 15, 2025: ₹1,709.40
    • May 22, 2025: ₹1,888.80
    • May 29, 2025: ₹2,114.20

    This upward trajectory reflects a consistent and robust growth pattern throughout the month.

    Catalysts Behind the Surge

    Several factors have contributed to this impressive rally:

    1. Operation Sindoor: The Indian government’s military response, Operation Sindoor, launched on May 7, 2025, significantly boosted investor confidence in defense stocks, including Zen Technologies.
    2. Strong Financial Performance: Zen Technologies reported a doubling of its revenue to ₹974 crore and a net profit increase to ₹299 crore in FY25, showcasing robust financial health.
    3. Increased Defense Spending: Investor optimism regarding increased military expenditure following a renewed ceasefire and stabilization along the India-Pakistan border further fueled the stock’s ascent.

    Technical Indicators

    Zen Technologies’ stock has been trading in the upper part of a strong rising trend in the short term, indicating a positive outlook. The stock holds buy signals from both short and long-term moving averages, suggesting continued upward momentum.

    Conclusion

    Zen Technologies’ substantial growth in May 2025 underscores its strong positioning in the defense sector and investor confidence in its future prospects. While the stock has experienced significant gains, potential investors should conduct thorough research and consider market conditions before making investment decisions.

    DISCLAIMER: This Blog is for informational purposes only and should not be construed as investment advice. Stock markets are subject to risks; please invest based on your risk profile

  • Novartis Launches Zero-Interest EMI Plan for Costly Heart Treatment Drug in India (2025)

    स्विट्जरलैंड की प्रमुख फार्मा कंपनी नवार्टिस ने भारत में दिल के रोगों के इलाज में उपयोग होने वाली अपनी महंगी दवा Sybrava (Inclisiran) को अधिक सुलभ बनाने के लिए एक अनोखी पहल की है। कंपनी ने इसके लिए बिना ब्याज वाली EMI (किस्त) योजना शुरू की है, जिससे आम मरीज भी अब इस आधुनिक उपचार का लाभ उठा सकेंगे।

    Sybrava (Inclisiran) क्या है?

    Sybrava, जिसे ग्लोबल स्तर पर Inclisiran कहा जाता है, एक नई पीढ़ी की कोलेस्ट्रॉल कम करने वाली इंजेक्टेबल दवा है। यह दवा शरीर में “खराब कोलेस्ट्रॉल” (LDL-C) को घटाने में मदद करती है। भारत में इसकी कीमत लगभग ₹1.2 लाख प्रति इंजेक्शन है, जिससे यह अब तक बहुत महंगे इलाज में गिनी जाती थी।

    EMI योजना की मुख्य बातें :

    नवार्टिस ने इस दवा को ज्यादा सुलभ बनाने के लिए भारतीय फिनटेक कंपनी Pine Labs के साथ साझेदारी की है। EMI योजना की खास बातें:

    • मासिक भुगतान: मरीजों को ₹15,000 से ₹16,000 प्रति माह की EMI में दवा उपलब्ध कराई जाएगी।
    • डोज़िंग शेड्यूल: पहली खुराक के बाद 90 दिन में दूसरी खुराक और फिर हर 180 दिन में एक इंजेक्शन देना होता है।
    • प्रमोशनल ऑफर: “Buy One, Get One” स्कीम के तहत पहली खुराक खरीदने पर दूसरी इंजेक्शन मुफ्त दी जा रही है (EMI स्कीम के अंतर्गत)।

    यह स्कीम उन मरीजों के लिए राहत लेकर आई है जो एक साथ इतनी बड़ी रकम नहीं चुका सकते थे।

    भारतीय कंपनियों से साझेदारी :

    नवार्टिस ने भारत में इस दवा के वितरण और मार्केटिंग के लिए कई प्रमुख दवा कंपनियों के साथ समझौता किया है:

    • Mankind Pharma – ब्रांड नाम: Crenzlo
    • JB Pharma – ब्रांड नाम: Izirize
    • Lupin – ब्रांड नाम: Tilpazan

    इन साझेदारियों का उद्देश्य दवा की पहुंच बढ़ाना और कीमत को नियंत्रण में रखना है। Mankind Pharma इसके साथ ही अन्य रोगी सहायता योजनाओं पर भी काम कर रही है।

    अब तक का असर :

    • जनवरी 2024 में भारत में लॉन्च के बाद से 3,000+ मरीजों ने Inclisiran से इलाज शुरू किया है।
    • अप्रैल 2024 के बाद से तीनों कंपनियों की संयुक्त बिक्री ₹7.7 करोड़ तक पहुंच चुकी है।
    • विशेषज्ञों का मानना है कि यह दवा खासकर उन मरीजों के लिए उपयोगी है जो स्टैटिन दवाओं से लाभ नहीं पा रहे हैं या उन्हें सहन नहीं कर पा रहे हैं।

    हेल्थकेयर में बदलाव की दिशा :

    नवार्टिस की यह EMI योजना स्वास्थ्य सेवाओं को अधिक लोगों के लिए सुलभ बनाने की दिशा में एक बड़ा कदम है। यह मॉडल भविष्य में अन्य महंगी दवाओं के लिए भी अपनाया जा सकता है। इससे आम मरीजों को आधुनिक इलाज समय पर मिल सकेगा और इलाज अधूरा रहने की आशंका कम होगी।

    निष्कर्ष: यह पहल सिर्फ एक फाइनेंशियल स्कीम नहीं है, बल्कि एक ऐसा मॉडल है जो भारत में हेल्थकेयर की पहुंच को व्यापक बना सकता है।

    EMI योजना या दवा से जुड़ी अधिक जानकारी के लिए अपने नजदीकी हृदय रोग विशेषज्ञ से संपर्क करें या Novartis India की वेबसाइट पर जाएं।

  • IndiGo Co-founder Rakesh Gangwal Sells 5.8% Stake Worth ₹11,928 Crore

    In a significant financial move, Rakesh Gangwal, co-founder of InterGlobe Aviation—the parent company of IndiGo Airlines—has sold a 5.8% stake in the company through a block deal valued at approximately ₹11,928 crore.

    Transaction Details

    • Shares Sold: Approximately 2.26 crore equity shares
    • Stake Percentage: 5.8% of InterGlobe Aviation
    • Sale Value: ₹11,928 crore
    • Floor Price: ₹5,260 per share, representing a ~3% discount to the previous closing price
    • Managing Banks: Goldman Sachs, Morgan Stanley, and JPMorgan facilitated the transaction

    Market Reaction

    Following the announcement, IndiGo’s stock experienced a dip of nearly 3% in early trading but later recovered some losses, trading at ₹5,318.00 per share, down 1.88% around 11 am.

    Company Performance

    Despite the stake sale, IndiGo reported strong financial results for Q4 FY25:

    • Net Profit: ₹3,067.5 crore, a 61.89% increase year-on-year
    • Revenue: ₹22,151.9 crore, up 24.3% from the previous year
    • EBITDAR: ₹6,948.2 crore, a 57.5% rise
    • Passenger Growth: 19.6% increase, reaching 3.19 crore travelers

    Strategic Implications

    This sale marks another step in Gangwal’s phased exit from IndiGo, which he co-founded in 2006. The Gangwal family’s stake has decreased from approximately 37% to 13.5% over the past three years.

    The transaction underscores a significant shift in IndiGo’s ownership structure and may influence future strategic decisions within the company.

  • Scoda Tubes IPO: Everything You Need to Know Before Investing

    Scoda Tubes Limited is a Gujarat-based manufacturer specializing in stainless steel tubes and pipes, including seamless and welded variants. Established in 2008, the company operates a manufacturing facility equipped with advanced machinery, such as a hot piercing mill, to produce mother hollow—a critical raw material for seamless products

    IPO Details

    • IPO Dates: May 28 – May 30, 2025
    • Issue Size: ₹220 crore (entirely fresh issue)
    • Price Band: ₹130 – ₹140 per share
    • Lot Size: 100 shares (minimum investment: ₹14,000)
    • Listing: BSE and NSE
    • Tentative Listing Date: June 4, 2025
    • Registrar: Link Intime India Pvt Ltd
    • Lead Manager: Monarch Networth Capital

    Financial Performance

    • Revenue Growth: From FY22 to FY24, Scoda Tubes achieved a Compound Annual Growth Rate (CAGR) of 44% in revenue, reaching ₹400 crore in FY24.
    • Profitability: Net profit grew at a CAGR of 235%, amounting to ₹18 crore in FY24.
    • Return Metrics: Return on Equity (RoE) stood at 28.77%, and Return on Capital Employed (RoCE) at 15.92% in FY24.

    IPO Objectives

    The proceeds from the IPO will be utilized for:

    • Expanding production capacity of seamless and welded tubes and pipes.
    • Meeting incremental working capital requirements.
    • General corporate purposes.

    Subscription Status (Day 1)

    • Overall Subscription: 1.77 times
    • Retail Investors: 1.8 times
    • Non-Institutional Investors (NII): 2.0 times
    • Qualified Institutional Buyers (QIBs): 1.4 times

    Grey Market Premium (GMP)

    • Current GMP: ₹18 – ₹23 per share
    • Estimated Listing Price: ₹158 (approx. 12.86% premium over the upper price band)
    • Trend: The GMP has shown slight fluctuations, with a peak at ₹23 and a low of ₹16 in recent sessions.

    Expert Opinions

    • Canara Bank Securities: Recommends ‘Subscribe’ for long-term investors, citing the company’s technical specialization, export growth, and alignment with industrial trends.
    • SBI Capital Securities: Also advises ‘Apply’, highlighting strong financial growth and favorable industry outlook.
    • Bajaj Broking: Maintains a ‘Neutral’ stance, suggesting a cautious approach due to certain risk factors.

    Risk Factors

    • Customer Concentration: Heavy reliance on select stockists for both domestic and international sales poses a concentration risk.
    • Cash Flow Efficiency: Concerns around cash flow management need to be addressed.
    • Capacity Utilization: Plans for significant capacity expansion despite currently low utilization rates may impact profitability.

    Conclusion

    The Scoda Tubes IPO presents a compelling opportunity for investors, backed by strong financial performance and a clear growth strategy. However, potential investors should weigh the associated risks, such as customer concentration and cash flow efficiency, before making an investment decision.

    Disclaimer: This blog is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult with a financial advisor before making investment decisions.